Process letters for TPG Capital’s up-for-sale clinical research business Novotech are in the post ahead of what’s expected to be a $4 billion sale to an offshore sponsor.
Lender sources told this column that TPG’s sell-side advisers, Goldman Sachs and Jefferies, were working with refreshed 2025 financial year numbers for the soon-to-be-dispatched information memorandum.
Loading...
Sarah Thompson has co-edited Street Talk since 2009, specialising in private equity, investment banking, M&A and equity capital markets stories. Prior to that, she spent 10 years in London as a markets and M&A reporter at Bloomberg and Dow Jones. Email Sarah at sarah.thompson@afr.com
Emma Rapaport is a co-editor of the Street Talk column. Prior to that, she was a markets reporter at The Australian Financial Review. Connect with Emma on Twitter. Email Emma at emma.rapaport@afr.com
